Category

Investing

Category

Mali’s government has begun seizing gold stockpiled at Barrick Gold’s (TSX:ABX,NYSE:GOLD) Loulo-Gounkoto mine, enforcing a provisional order issued last week amid a dispute over changes to the nation’s mining rules.

The seizure was confirmed by Barrick in a memo to staff, according to a Monday (January 13) Reuters report. The military-led government continues to claim a greater share of mining revenues from foreign operators.

The enforcement began on Saturday (January 11), as per Barrick’s memo, which notes that the company may be compelled to suspend operations at the site if the issue remains unresolved.

Loulo-Gounkoto contributes significantly to Barrick’s global production, and is set to account for about 14 percent of its gold output for 2025. Barrick has an 80 percent stake, with the Malian government owning the remaining 20 percent.

While Barrick has not disclosed the exact volume of gold affected, internal estimates suggest that around 4 metric tons of gold, valued at approximately US$380 million based on the current spot price, are at stake.

Multiple sources told Reuters on Monday that around 3 metric tons had already been seized from the site by helicopter as of Saturday, with one source valuing the seized gold at US$245 billion.

The move comes amid ongoing tensions over the Malian government’s claims of unpaid taxes and dividends. Mali claims the company owes US$512 million in unpaid taxes and dividends, a claim Barrick has rejected.

On January 6, the company warned it would have to halt operations if the government continued to restrict gold shipments. Barrick is seeking arbitration through the International Center for the Settlement of Investment Disputes.

The conflict has led to multiple detentions of Barrick executives, with the most recent occurring in November, after negotiations between broke down. In early December, the country issued an arrest warrant for CEO Mark Bristow.

Mali changes mining code post-coup

Gold is Mali’s primary export, contributing over 80 percent of the country’s total export revenues in 2023. The West African country’s government has been led by the military since a 2021 coup.

In 2023, Mali introduced a new mining code that aims to raise its stake in mining operations from 20 to 35 percent. It also allows the government to collect 7.5 percent of sales revenue when the gold price exceeds US$1,500 per ounce.

Last year, following an audit into the mining sector, Mali began pursuing alleged back taxes and dividends owed by international mining companies working in the country.

Finance Minister Alousseni Sanou said Mali expects to collect 750 billion CFA francs, about US$1.2 billion, from miners in the first quarter of 2025, following a similar collection of 500 billion CFA francs in late 2024.

Some companies have already come to agreements with the Malian government. For example, B2Gold (TSX:BTO,NYSEAMERICAN:BTG) reached a new agreement last September for its Fekola operations. It includes financial settlements and a commitment from Mali to expedite permitting for the Fekola underground mine.

Australia’s Resolute Mining (ASX:RSG,LSE:RSG) resolved a tax dispute with the government in November 2024 by agreeing to pay US$160 million after its CEO and two other executives were detained in Mali.

Barrick’s dispute remains unresolved at this time.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ahead after declining earnings in recent years.

According to ZS consultant Cody Powers, lower interest rates could increase investment in biopharma, boosting research and development (R&D) into promising new indications, mergers and acquisitions (M&A) and clinical trials.

Industry executives polled for Deloitte’s 2025 life science outlook anticipate revenue growth and margin expansion, leading to increased investment in key therapeutic areas such as oncology, immunology, neurology and, of course, treatments for obesity and diabetes. This renewed focus on innovation, coupled with a changing regulatory environment, is expected to drive interest in the sector that could reshape the competitive landscape.

Key therapeutic areas in 2025

PurpleLab data (via Axios) shows roughly a 10 percent increase in sales for GLP-1s in 2024, with continued growth predicted for 2025 due to sustained demand, according to Evaluate’s 2025 Pharma Preview.

After exceeding US$1 billion in 2024, the most recent forward-looking projections of GLP-1 sales from industry leaders Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) are strong, with Novo aiming to capture more than a third of the global market share of diabetes care in 2025.

To keep up with demand, both companies are addressing previous production constraints by expanding manufacturing capacity. Novo Nordisk acquired contract manufacturer Catalent in a US$16.5 billion deal, finalizing the sale in December 2024 and securing itself as a key player in the supply chain. Meanwhile, Eli Lilly is bolstering its internal manufacturing with a new US$4.5 billion manufacturing and research and development (R&D) center in Indiana slated to open in late 2027.

In the meantime, Lilly is also expanding its existing facility in Wisconsin and has reportedly partnered with CDMOs National Resilience and BSP Pharmaceuticals to meet immediate needs.

Beyond manufacturing, both companies are making strategic moves to maintain their market dominance amidst the entry of biosimilars from corporations like Teva Pharmaceuticals and pharma companies in China.

Eli Lilly’s partnership with digital health company Ro expands patient access to its medications via telehealth, while its lower-priced single-dose vials of Zepbound lower the cost barriers for the self-pay market.

Moreover, innovation remains a key driver. Eli Lilly is actively testing tirzepatide for indications against MASH and chronic kidney disease and its oral GLP-1 agonist orforglipron is in Phase III trials for obstructive sleep apnea in addition to obesity and type II diabetes.

Novo Nordisk is also exploring new indications for semaglutide, including MASH, and as a potential treatment for Alzheimer’s disease.

According to Evaluate analysts, the field of oncology continues to be another evolving area within the pharmaceutical industry. While traditional cancer treatments remain relevant, there has been a notable shift in R&D focus towards more targeted approaches.

Antibody-drug conjugates (ADCs) have emerged as a promising avenue in oncology research in recent years and have shown potential in improving treatment outcomes for various types of cancer. Clinical trials examining the efficacy of Merck’s (NYSE:MRK) Keytruda, an immune checkpoint inhibitor, with various ADCs showed promising results compared to standard chemo treatments. An ongoing trial, DESTINY-Breast09, is investigating the combination of AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo’s (OTCPINK:DSKYF) Enhertu and Keytruda in HER2-positive breast cancer, with primary completion data likely due in Q3 2025.

These trials could unlock new treatment options and expand the market for these already successful ADCs.

Similarly, bispecific antibodies have garnered significant attention in the oncology space, demonstrating efficacy in hematologic malignancies. A trial directly comparing Keytruda to Ivonescimab, a bispecific antibody under development by Chinese pharma company Akeso Biopharma (OTCPINK:AKESF) and licensed by Summit Therapeutics (NASDAQ:SMMT), resulted in ivonescimab leading to a better overall survival rate than Keytruda. Further testing is required, but the suggested outcome could impact the future development and potential commercial success of ivonescimab and the bispecific antibody mechanism overall.

Another area of renewed interest in recent months is bispecific antibodies targeting the TIGIT immune checkpoint. While Roche (OTCQX:RHHBF) and its subsidiary Genentech’s tiragolumab faced a setback in a Phase III trial, Gilead (NASDAQ:GILD) and Arcus Biosciences (NYSE:RCUS) have shown promising results with their anti-TIGIT drug domvanalimab.

In a Phase I trial, domvanalimab plus anti-PD-1 antibody zimberelimab led to a 36 percent reduction in the risk of death for patients with advanced non-small cell lung cancer compared to patients who took zimberelimab alone.

“These are the first results demonstrating an improvement in overall survival reported for domvanalimab and zimberelimab,” said Dimitry Nuyten, chief medical officer of Arcus, sharing the results at the Society for Immunotherapy of Cancer (SITC) annual meeting in November 2024.

“They add to the growing body of evidence that domvanalimab…may have a differentiated efficacy, safety and tolerability profile relative to published data from studies with Fc-enabled anti-TIGIT antibodies.”

While immunology remains a key area of pharmaceutical investment following the success of interleukin inhibitors Dupixent, jointly developed and commercialized by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN); and Skyrizi, developed and marketed by AbbVie (NYSE:ABBV), the sector is also experiencing shifts.

On January 13, amidst declining demand for Covid-19 and respiratory syncytial virus, Moderna (NASDAQ:MRNA) one of the most prominent names in immunology, cut its sales forecast for 2025. The company expects 2025 revenue of between US$1.5 billion to US$2.5 billion, down from its previous projection of between US$2.5 billion and US$3.5 billion.

Pharma regulation to shape investment decisions in 2025

Changes in the pharmaceutical industry’s heavily regulated environment could impact how companies make investment decisions in 2025. While Big Pharma may be hopeful that President-elect Trump will ease drug price negotiation rules, he has been relatively quiet about repealing that aspect of the Inflation Reduction Act (IRA). His stance on the Affordable Care Act (ACA) is unclear, but he has been vocal about his intentions to trim federal funding for various programs.

The ACA currently provides health insurance coverage to over 45 million Americans. Changes to coverage could have ripple effects throughout the healthcare sector, including the pharmaceutical industry, as reduced coverage could lead to decreased demand for certain medications.

If IRA provisions remain in place or are strengthened, they could put downward pressure on drug prices, potentially impacting company revenues and investor returns. Conversely, if these provisions are weakened or repealed, it could provide a boost to the industry. Investors will need to closely observe political developments and any signals regarding the future of the IRA.

Trump’s unconventional nominees for key health and regulatory positions add another layer of complexity. During his announcement naming celebrity Dr. Mehmet Oz as his choice for administrator of the Centers for Medicare and Medicaid Services (CMS), Trump said Dr. Oz would “cut waste and fraud within our country’s most expensive government agency,” prompting analysts to speculate that he may alter rules on who qualifies for Medicaid and Medicare by instituting work requirements to receive them.

Robert F. Kennedy Jr. (RFK) as Secretary of Health and Human Services (HHS) could impact pharma companies developing vaccines due to his skepticism; however, he has clarified that he supports rigorous research into vaccine safety rather than eliminating them entirely; Research and testing, however, are expensive.

The nomination of Dr. Marty Makary as FDA Commissioner has been met with optimism from some market analysts, who anticipate a potentially more streamlined drug approval process. This could be a positive sign for investors, as faster approvals mean quicker market entry for new drugs and potentially faster returns on investment.

Investor takeaway

Overall, the pharmaceutical industry in 2025 is expected to be characterized by innovation, growth, and transformation. While challenges remain, the industry’s focus on research and development, coupled with advancements in technology and a commitment to patient care, is expected to drive progress and deliver significant benefits to patients worldwide.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Today’s pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for COVID-19 vaccines. However, the industry’s major underlying drivers — higher rates of cancer and chronic diseases — are still at play.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year’s FDA approvals for pharmaceuticals included Eli Lilly and Company’s (NYSE:LLY) Alzheimer’s disease treatment Kisunla (donanemab-azbt).

Big pharma largely stole the show throughout the course of the past year, but a number of small- and mid-cap NASDAQ pharma stocks have also made gains.

1. Chimerix (NASDAQ:CMRX)

Year-over-year gain: 239.49 percent
Market cap: US$297.69 million
Share price: US$3.31

Chimerix is a clinical-stage company developing medicines to improve the quality of life for patients facing deadly diseases. Its most advanced drug development program is ONC201 (dordaviprone), which is in development for recurrent H3 K27M-mutant glioma, a lethal form of brain cancer.

After trading mostly sideways for much of the past year, shares of Chimerix received a big boost late in the fourth quarter of 2024 as the company reached important milestones in its drug development program. The stock jumped more than 217 percent on December 10 to US$2.76, one day after Chimerix announced it would submit a New Drug Application for accelerated approval of dordaviprone to the FDA before the end of the year.

The company’s stock price continued to gain momentum in the following weeks to push past the US$3 mark by December 23. The day following Chimerix’ December 30 press release confirming it had completed the submission process, the stock reached US$3.48 per share.

“With this submission, we now turn our attention to preparing for potential commercial launch in the U.S. next year,” stated Chimerix CEO Mike Andriole.

Chimerix shares hit a yearly high of US$3.66 on January 7, 2025.

2. Eton Pharmaceuticals (NASDAQ:ETON)

Year-over-year gain: 195.98 percent
Market cap: US$372.89 million
Share price: US$14.00

Eton Pharmaceuticals is developing and commercializing treatments for ultra-rare diseases. Its commercial portfolio of rare disease products includes Alkindi Sprinkle, Increlex, PKU Golike and multiple FDA-approved generic bioequivalents. The company also has several product candidates in late-stage development: hydrocortisone oral solution ET-400, ET-600 for diabetes insipidus and the ZENEO hydrocortisone autoinjector.

Eton’s share price performed exceptionally well in the second half of 2024 and into the first few weeks of 2025 on robust quarterly financials, acquisitions and key milestones.

The stock made steady gains following the release of the company’s Q2 2024 financial report in early August. The quarter brought royalty revenue of US$9.1 million and a 40 percent increase in product sales over Q2 2023, representing “the 14th straight quarter of sequential product sales growth.” Shares in Eton climbed by more than 65 percent to US$6.00 by the end of Q3.

In early October, the company announced the acquisition of Increlex, a medication used in the treatment of pediatric patients with severe IGF-1 deficiency, from French biopharma company Ispen. By the end of the month, Eton’s stock reached a value of US$8.62 per share.

November was a busy month for positive news flow out of Eton. The company was awarded a second patent for its liquid formulation of hydrocortisone on November 7. A few days later, its Q3 2024 report highlighted another consecutive quarter of growth in product sales, up 40 percent year-over-year. Eton closed out the month with the acquisition of the US rights to Amglidia for the treatment of neonatal diabetes mellitus from French biotech firm AMMTeK.

By the end of November, Eton’s stock price had surged to US$13.53 per share. The stock reached its highest yearly value of US$14.31 on January 2, 2025. The next day, Eton announced the acquisition of Galzin, an FDA-approved treatment for patients with Wilson disease, which it plans to begin commercializing in the US early this year.

3. Corvus Pharmaceuticals (NASDAQ:CRVS)

Year-over-year gain: 139.63 percent
Market cap: US$334.14 million
Share price: US$5.20

Corvus Pharmaceuticals is a clinical-stage biopharma company developing an immunotherapy platform based on ITK inhibition for the treatment of various cancer and immune diseases. The company’s lead product candidate is soquelitinib, an investigational small molecule drug that selectively inhibits ITK and is delivered orally.

Corvus is another NASDAQ pharma stock that saw significant gains in the last half of 2024.

The growth in its share price got its first major boost in early August when the FDA granted fast track designation to soquelitinib ‘for the treatment of adult patients with relapsed or refractory peripheral T cell lymphoma after at least two lines of systemic therapy.’ By the end of the month, shares in Corvus had grown by nearly 50 percent to US$4.48.

Corvus’ stock value received another bump to the upside following the September 10 announcement it had initiated registration in its Phase 3 clinical trial of soquelitinib for the aforementioned indication. Shares in the company reached what was then their highest point of US$5.91 on September 20, and continued to gain value throughout the following weeks to hit a current yearly high of US$9.56 on November 11.

4. ATyr Pharma (NASDAQ:ATYR)

Year-over-year gain: 110.9 percent
Market cap: US$276.17 million
Share price: US$3.29

ATyr Pharma is using its proprietary tRNA synthetase platform, which includes a library of domains derived from all 20 tRNA synthetases, to develop new therapies for fibrosis and inflammation. The company’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator targeting interstitial lung disease.

The fourth quarter of 2024 was very good to aTyr’s stock value, and it has continued to perform well into January 2025.

In early October, aTyr Pharma announced the publication of an analysis of the Phase 1b/2a clinical trial of efzofitimod in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in the European Respiratory Journal.

Shares in aTyr Pharma climbed by more than 92 percent through the month to a then yearly high of US$3.35 on October 22.

On December 10, the company shared its third positive safety review of its ongoing Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis. Shares of the company hit their highest yearly value of US$3.98 on January 3.

5. Inhibikase Therapeutics (NASDAQ:IKT)

Company Profile

Year-over-year gain: 90 percent
Market cap: US$178.73 million
Share price: US$2.66

Inhibikase Therapeutics is developing protein kinase inhibitor therapeutics for modifying the course of cardiopulmonary and neurodegenerative disease through Abl kinase inhibition. Its two leading drug candidates are IkT-001Pro, a prodrug of imatinib mesylate, for pulmonary arterial hypertension with fewer on-dosing side-effects; and risvodetinib, a selective c-Abl inhibitor to treat Parkinson’s and Parkinson’s-related disease.

In late October, Inhibikase closed on an approximately US$110 million private placement, which with the full cash exercise of accompanying warrants could lead to a potential aggregate financing of up to approximately US$275 million before deducting fees and expenses. The company intends to use the funds in part for its Phase 2b 702 trial for IkT-001Pro in pulmonary arterial hypertension.

Shares of Inhibikase reached a yearly high of US$3.97 on December 17.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Today’s pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for COVID-19 vaccines. However, the industry’s major underlying drivers — higher rates of cancer and chronic diseases — are still at play.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year’s FDA approvals for pharmaceuticals included Eli Lilly and Company’s (NYSE:LLY) Alzheimer’s disease treatment Kisunla (donanemab-azbt).

Big pharma largely stole the show throughout the course of the past year, but a number of small- and mid-cap NASDAQ pharma stocks have also made gains.

1. Chimerix (NASDAQ:CMRX)

Year-over-year gain: 239.49 percent
Market cap: US$297.69 million
Share price: US$3.31

Chimerix is a clinical-stage company developing medicines to improve the quality of life for patients facing deadly diseases. Its most advanced drug development program is ONC201 (dordaviprone), which is in development for recurrent H3 K27M-mutant glioma, a lethal form of brain cancer.

After trading mostly sideways for much of the past year, shares of Chimerix received a big boost late in the fourth quarter of 2024 as the company reached important milestones in its drug development program. The stock jumped more than 217 percent on December 10 to US$2.76, one day after Chimerix announced it would submit a New Drug Application for accelerated approval of dordaviprone to the FDA before the end of the year.

The company’s stock price continued to gain momentum in the following weeks to push past the US$3 mark by December 23. The day following Chimerix’ December 30 press release confirming it had completed the submission process, the stock reached US$3.48 per share.

“With this submission, we now turn our attention to preparing for potential commercial launch in the U.S. next year,” stated Chimerix CEO Mike Andriole.

Chimerix shares hit a yearly high of US$3.66 on January 7, 2025.

2. Eton Pharmaceuticals (NASDAQ:ETON)

Year-over-year gain: 195.98 percent
Market cap: US$372.89 million
Share price: US$14.00

Eton Pharmaceuticals is developing and commercializing treatments for ultra-rare diseases. Its commercial portfolio of rare disease products includes Alkindi Sprinkle, Increlex, PKU Golike and multiple FDA-approved generic bioequivalents. The company also has several product candidates in late-stage development: hydrocortisone oral solution ET-400, ET-600 for diabetes insipidus and the ZENEO hydrocortisone autoinjector.

Eton’s share price performed exceptionally well in the second half of 2024 and into the first few weeks of 2025 on robust quarterly financials, acquisitions and key milestones.

The stock made steady gains following the release of the company’s Q2 2024 financial report in early August. The quarter brought royalty revenue of US$9.1 million and a 40 percent increase in product sales over Q2 2023, representing “the 14th straight quarter of sequential product sales growth.” Shares in Eton climbed by more than 65 percent to US$6.00 by the end of Q3.

In early October, the company announced the acquisition of Increlex, a medication used in the treatment of pediatric patients with severe IGF-1 deficiency, from French biopharma company Ispen. By the end of the month, Eton’s stock reached a value of US$8.62 per share.

November was a busy month for positive news flow out of Eton. The company was awarded a second patent for its liquid formulation of hydrocortisone on November 7. A few days later, its Q3 2024 report highlighted another consecutive quarter of growth in product sales, up 40 percent year-over-year. Eton closed out the month with the acquisition of the US rights to Amglidia for the treatment of neonatal diabetes mellitus from French biotech firm AMMTeK.

By the end of November, Eton’s stock price had surged to US$13.53 per share. The stock reached its highest yearly value of US$14.31 on January 2, 2025. The next day, Eton announced the acquisition of Galzin, an FDA-approved treatment for patients with Wilson disease, which it plans to begin commercializing in the US early this year.

3. Corvus Pharmaceuticals (NASDAQ:CRVS)

Year-over-year gain: 139.63 percent
Market cap: US$334.14 million
Share price: US$5.20

Corvus Pharmaceuticals is a clinical-stage biopharma company developing an immunotherapy platform based on ITK inhibition for the treatment of various cancer and immune diseases. The company’s lead product candidate is soquelitinib, an investigational small molecule drug that selectively inhibits ITK and is delivered orally.

Corvus is another NASDAQ pharma stock that saw significant gains in the last half of 2024.

The growth in its share price got its first major boost in early August when the FDA granted fast track designation to soquelitinib ‘for the treatment of adult patients with relapsed or refractory peripheral T cell lymphoma after at least two lines of systemic therapy.’ By the end of the month, shares in Corvus had grown by nearly 50 percent to US$4.48.

Corvus’ stock value received another bump to the upside following the September 10 announcement it had initiated registration in its Phase 3 clinical trial of soquelitinib for the aforementioned indication. Shares in the company reached what was then their highest point of US$5.91 on September 20, and continued to gain value throughout the following weeks to hit a current yearly high of US$9.56 on November 11.

4. ATyr Pharma (NASDAQ:ATYR)

Year-over-year gain: 110.9 percent
Market cap: US$276.17 million
Share price: US$3.29

ATyr Pharma is using its proprietary tRNA synthetase platform, which includes a library of domains derived from all 20 tRNA synthetases, to develop new therapies for fibrosis and inflammation. The company’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator targeting interstitial lung disease.

The fourth quarter of 2024 was very good to aTyr’s stock value, and it has continued to perform well into January 2025.

In early October, aTyr Pharma announced the publication of an analysis of the Phase 1b/2a clinical trial of efzofitimod in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in the European Respiratory Journal.

Shares in aTyr Pharma climbed by more than 92 percent through the month to a then yearly high of US$3.35 on October 22.

On December 10, the company shared its third positive safety review of its ongoing Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis. Shares of the company hit their highest yearly value of US$3.98 on January 3.

5. Inhibikase Therapeutics (NASDAQ:IKT)

Company Profile

Year-over-year gain: 90 percent
Market cap: US$178.73 million
Share price: US$2.66

Inhibikase Therapeutics is developing protein kinase inhibitor therapeutics for modifying the course of cardiopulmonary and neurodegenerative disease through Abl kinase inhibition. Its two leading drug candidates are IkT-001Pro, a prodrug of imatinib mesylate, for pulmonary arterial hypertension with fewer on-dosing side-effects; and risvodetinib, a selective c-Abl inhibitor to treat Parkinson’s and Parkinson’s-related disease.

In late October, Inhibikase closed on an approximately US$110 million private placement, which with the full cash exercise of accompanying warrants could lead to a potential aggregate financing of up to approximately US$275 million before deducting fees and expenses. The company intends to use the funds in part for its Phase 2b 702 trial for IkT-001Pro in pulmonary arterial hypertension.

Shares of Inhibikase reached a yearly high of US$3.97 on December 17.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Rare earths prices saw some gains in May 2024, fueled by positive sentiment over consumer demand in China.

While both dysprosium (Dy) and neodymium-praseodymium (NdPr) oxides benefited from this positivity, Benchmark Mineral Intelligence notes that Dy oxides registered the largest gain, moving 10 percent high month-on-month.

“This was the first-time rare earths prices had recovered after a continuous decline (in 2023), but after a brief recovery, prices are now falling again,” Benchmark pricing and data analyst George Ingall said in a May report.

The move for Dy oxides was more pronounced as the market is smaller. NdPr oxide was up a more moderate 0.6 percent.

Muted demand has weighed on prices, but year-on-year increases in mine supply have also capped price growth.

Global rare earths output has rapidly risen from 240,000 metric tons in 2020 to 350,000 metric tons in 2023, according to US Geological Survey data. The lion’s share of rare earth production continues to be dominated by China, a factor that remains relevant for the industry as the Asian nation continues to flex its control.

East vs. west divide still key for rare earths

Rare earths, which are essential in various high-tech applications, including electric vehicles (EVs), wind turbines and electronics, have become a political pawn between the east and west.

Currently, China and the US are locked in a geopolitical struggle over rare earths, with tensions mounting.

In late 2023, China imposed bans on exporting technologies for rare earths processing, tightening its grip on the global supply chain. By mid-2024, reports were circulating that the country’s State Council would introduce stricter regulations on domestic rare earths mining, smelting and trading, effective October 1, 2024. The rules would declare rare earth resources state-owned and require companies to maintain detailed records in a traceability system.

The US responded with tariffs on Chinese EVs and critical minerals, aiming to counter China’s dominance while bolstering domestic production. These measures underscore escalating tensions, with both nations prioritizing strategic control over rare earths amid growing demand for green technologies and national security needs.

“There is a potential fork in the path regarding critical materials, more broadly, and rare earths, in particular, when it comes to overall trade strategy between western nations and China,” he said via email.

“By my calculations, if we maintain an integrated trade structure, then, together, we will probably be able to provide sufficient quantities of both NdPr and DyTb (dysprosium-terbium) to achieve our goals in both the automotive and clean energy sectors; NdPr is easy, DyTb is harder, but it can be done.”

However, if western nations decide they want to exclude China they will face shortfalls.

“If we decide to go our own way in the west, then we can likely deliver enough NdPr to do what we need to do. (But) we are unlikely to make enough DyTb to enable the intended use of all that NdPr,’ he noted.

Hykawy also took aim at governments not recognizing the increasing importance of DyTb.

“At present, there is some noise and support for ‘rare earths,’ but no one in government seems to understand that the critical materials out of the lanthanide elements is shifting from NdPr to DyTb. Without that realization, the steps that are being taken are not mitigating the correct risks,” he said.

Ex-China rare earths supply in the works

To combat China’s hold on the rare earths sector, the US is heavily investing in the space.

In April 2024, the US Department of Energy earmarked US$17.5 million for four rare earths and critical minerals and materials processing technologies using coal and coal by-products as feedstocks.

“In addition, the US government has provided financing for rare earth processing facilities under development by existing rare earth producers to be located in the US, along with NdFeB (neodymium-iron-boron) magnet production facilities.”

To bolster domestic magnet production against Chinese competition, the US government plans to impose a 25 percent tariff on NdFeB magnet imports from China starting in 2026.

However, since most NdFeB magnets are already embedded in components imported by US manufacturers, the tariff is expected to affect only a small fraction of the country’s overall NdFeB magnet consumption, Merriman said.

As the US looks to build out a domestic rare earths supply chain, China has sought to fortify its own.

“China has also taken action to reduce supply chain risk for rare earths, both at the sourcing of feedstocks and the downstream finished product stage,” he said. “China via state-owned companies has invested in several foreign rare earth operations to diversify the origin of rare earth feedstocks, particularly for heavy rare earth rich feeds.”

As Merriman pointed out, the diversification has been propelled by sourcing issues in 2024.

“The risk of China’s current feedstock sources has been highlighted in 2024 with disruption to feedstock supplies from Myanmar, which accounted for >40 percent of global mine supply of dysprosium and terbium,” he said.

In October, rare earths supply was interrupted when Myanmar’s Kachin Independence Army seized Panwa, a key rare earths mining hub, following the earlier capture of Chipwe.

The two towns in Kachin state, near China’s Yunnan province, are critical suppliers of rare earth oxides to China.

“Chinese imports of raw materials from Myanmar were 40,000 tonnes during the first nine months of 2024,” If that production drops out, there will be a big impact on (heavy) rare earth prices,” Thomas Kruemmer, founder of the Rare Earths Observer, told Fastmarkets.

Rare earths project pipeline facing fragility

Depressed prices through 2023 have weighed on explorers and developers as new projects are financially unviable.

“There are several projects which are at advanced stages of development, though few are able to compete on a cost basis with fully integrated and state-owned operators in China,” said Merriman.

“Financing, metallurgical test work and the development of a sizable terminal market outside of China for semi-refined rare earth products are all barriers to the development of several rare earth projects.”

Weak markets are often fertile ground for M&A and deals, and 2024 saw some notable ones.

In June, Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands project.

Since the agreement was penned, development activities at Donald have progressed, including work related to process plant engineering, auxiliary infrastructure, contract tendering and permitting and approvals.

In September, Defense Metals (TSXV:DEFN,OTCQB:DFMTF) signed a memorandum of understanding with the Saskatchewan Research Council (SRC) to support the development of a domestic rare earths supply chain.

Defense Metals and the SRC will explore collaborations on rare earth processing and supply, including using SRC’s proprietary separation technology for Defense Metals’ products. They aim to negotiate a long-term supply agreement as Defense Metals advances its Wicheeda rare earths project in BC, Canada.

As the year drew to a close, Ucore Rare Metals (TSXV:UCU,OTCQX:UURAF) received a US$1.8 million payment from the US Department of Defense on December 13. The funding will support Ucore’s subsidiary, Innovation Metals, in demonstrating its RapidSX rare earths separation technology at a commercial demonstration facility in Kingston, Ontario.

What factors will affect rare earths in 2025?

In 2025, Merriman sees China’s continued rare earths dominance as a key driver for the sector.

“China maintains a strong influence over rare earth pricing, with most international prices for rare-earth trades being based in some way upon Chinese domestic pricing. China has long sought price stability for key rare earths, allowing downstream value add industries to benefit from reliable and often lower feedstock prices,’ he said.

For Hykawy, precarious supply outside of China and weak prices will be a focal point in 2025.

‘Obviously, we’ve seen significant price drops for Nd, for example,’ he said.

‘That helps the auto sector, but only by the slightest amount. Let’s say there is 2 kilograms of magnet in a main motor in an EV, and I’m likely overestimating. Only 27 percent of that is neodymium metal. The impact of the price change on 500 grams of rare earth is not moving the needle on an EV’s cost,’ Hykawy added.

He also expressed concern about the supply chain for heavy rare earths. “The bigger, long-term impact I am thinking about is, as Dy and Tb production becomes a bottleneck, how does the industry adjust to a world where the projects that can produce enough Dy and Tb are also making Nd and Pr as a by-product?” he posited.

‘To meet the growing demand for heavy rare earths, do the major NdPr producers, like Lynas Rare Earths (ASX:LYC,OTC Pink:LYSCF), MP Materials (NYSE:MP) and the Bayan Obo mine, drop their NdPr output to maintain reasonable prices, or do they keep going and flood the market and drop their own prices to unsustainable levels,’ he questioned.

“For some time, NdPr have been the materials in demand. Soon, they might be valuable but overproduced commodities, with everyone scrambling to get the right amount of DyTb for their automotive or wind application.”

Securities Disclosure: I, Georgia Williams, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Zinc was among the best-performing base metals in 2024.

It experienced a 13 percent gain, rising from US$2,621 per metric ton (MT) to US$2,979 by the end of the year.

Like copper, zinc faced concentrate shortages in 2024. This situation has led to curtailments at Chinese refiners, which have been forced to compete for limited raw material. Large purchases from exchange warehouses have exacerbated the situation, reducing the amount of refined zinc available to the broader market.

What other factors impacted the zinc market last year? Read on to find out.

How did zinc prices perform in 2024?

In the first half of 2024, the zinc market reacted to fallout from Q4 2023 production cuts.

An oversupply situation that drove prices down at the end of 2023 forced operators to curtail output, as high costs made production unsustainable. However, these cuts had little effect, and by the end of the first quarter, aboveground supplies at London Metal Exchange (LME) warehouses had surged to over 270,000 MT.

That supply/demand backdrop provided opportunities for some companies — in early April, Canada’s Teck Resources (TSX:TECK.A,TECK.B,NYSE:TECK) was able to strike a deal with Korea Zinc (KRX:010130) that will see Teck pay US$165 per MT for treatment charges — that’s the lowest amount since 2021 and a 40 percent discount over 2023.

In Q2, a price run failed to maintain momentum, as the market lacked the fundamentals to sustain its rise.

Higher zinc prices came alongside speculation of a US Federal Reserve interest rate cut and renewed hope that rule changes for the Chinese housing markets would boost zinc’s fortunes.

However, by the end of Q2, the Chinese housing market had failed to improve — in fact, the slowdown in the sector had accelerated, with the value of new home sales in July slipping 19.7 percent from the same period one year earlier.

A Fed rate cut also didn’t materialize, with the expectation of when it would happen pushed back to July and then September, when the central bank ultimately made a jumbo-sized 50 basis point cut.

Zinc price, H2 2024.

Zinc price, H2 2024.

Chart via Trading Economics.

As H2 began, the price of zinc was US$2,928.50, slightly off its first-half high of US$3,139.50 set on May 21. The metal continued to decline as July wore, falling to its H2 low of US$2,581.50 on August 7.

The next two months saw zinc experience significant volatility. It reached a peak of US$2,943 on August 27, slipped back to US$2,712 on September 10 and then rebounded to a yearly high of US$3,198 on October 2.

Zinc remained rangebound above US$3,000 for much of Q4. It fell below that mark on November 8, but by November 25 it was once again trading above that level. Zinc ended the year at US$2,978.50 on December 31.

What factors impacted the zinc market in 2024?

The most significant contributor to zinc’s price rise in H2 was the lack of concentrate available to Chinese refiners, which are responsible for more than half the global supply of refined zinc. This resulted in increased competition, with some smelting operations reducing their treatment charges to under US$0 per MT.

Ultimately, 14 processors agreed to curtailments that would reduce their 2024 ore demand by nearly 1 million MT.

Despite the cuts, Reuters columnist Andy Home wrote at the end of August that the global refined zinc market was in surplus by 228,000 MT during H1, with much of that material finding its way to LME warehouses.

Also important in H2 were several large purchases of refined zinc from LME warehouses. Gains were fueled after 106,775 MT were removed from the LME network, leaving just 154,125 MT available, the lowest since November 2023.

At least some of the metal seemed destined for Trafigura, a leading trader and refiner of the metal, but the company declined to comment on the purchase. The move is reminiscent of Citi’s (NYSE:C) zinc purchases from LME stockpiles during the second half of 2023 — the firm requested delivery of 40,000 MT of zinc at the time.

For now, the market remains weak on the demand side. More than half of refined zinc is used in the production of galvanized steel destined for the construction sector, which has been weak in China and Europe.

A raft of new stimulus measures in China have yet to affect the broader economy, and the country’s real estate sector is still reeling from the collapse of top construction firms.

Meanwhile, in Europe, the construction sector has been affected by the dual impact of high inflation and high interest rates. With the post-pandemic outlook coming into better balance, the industry is expected to rebound in 2025.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

As data breaches and cyberattacks rise, cybersecurity exchange-traded funds (ETFs) are gaining traction.

The term cybersecurity originated in 1989, and today is defined as the measures taken to protect a computer or computer system against unauthorized access or cyberattack threats. These measures can include people, policies and processes.

The number of security incidents is increasing every year, as are the costs companies must pay. In fact, according to a 2024 research report from IBM (NYSE:IBM), the average cost of a single data breach event globally was US$4.48 million — up 10 percent over the previous year and the highest cost in the 19 years since the first report was issued.

These threats are unlikely to fade anytime soon. The forecast for the cybersecurity market is strong through 2030, with trends in the space including the threats posed by AI and quantum computing.

There are multiple ways to invest in the cybersecurity market, including cybersecurity ETFs, which offer a low-cost way to enter the space. ETF fees and expenses are typically lower than those associated with mutual funds or other types of actively managed financial instruments. What’s more, ETFs provide exposure to a basket of stocks, meaning investors can spread their risk around.

According to ETF.com, there are nine cybersecurity ETFs listed in the US. Here’s a closer look at the top four cybersecurity ETFs by assets under management (AUM). ETFs with assets under management above US$500 million are included in this list. All numbers and figures were current as of January 9, 2025.

1. First Trust NASDAQ Cybersecurity ETF (NASDAQ:CIBR)

Company Profile

AUM: US$7.08 billion
Expense ratio: 0.6 percent

Launched in July 2015, this ETF tracks the NASDAQ CTA Cybersecurity Index (INDEXNASDAQ:NQCYBR) and has 33 holdings. The index, which includes companies categorized by the Consumer Technology Association as cybersecurity, is largely composed of tech firms but also offers some exposure to the defense and aerospace sectors.

The First Trust NASDAQ Cybersecurity ETF’s top holdings include Broadcom (NASDAQ:AVGO) at a weight of 10.95 percent, Infosys (NYSE:INFY) at an 8.14 percent weight, CrowdStrike Holdings (NASDAQ:CRWD) at 7.98 percent and Cisco Systems (NASDAQ:CSCO) at 7.85 percent.

2. ETFMG Prime Cyber Security ETF (ARCA:HACK)

Company Profile

AUM: US$1.81 billion
Expense ratio: 0.6 percent

The oldest cybersecurity ETF on this list is the ETFMG Prime Cyber Security ETF, which began trading in November 2014 and tracks the ISE Cyber Security Index (INDEXNASDAQ:HXR). HACK is run by ETFMG, a lesser-known company among the goliath ETF managers, and it has had a 12.19 percent annualized return over the past five years.

The cybersecurity ETF has 27 holdings, and its top holdings by weight include Broadcom at 13.87 percent, Cisco Systems at 7.18 percent, CrowdStrike Holdings at 5.62 percent and Palo Alto Networks (NYSE:PANW) at 5.45 percent.

3. iShares Cybersecurity and Tech ETF (ARCA:IHAK)

Company Profile

AUM: US$921.99 million
Expense ratio: 0.47 percent

Last on this cybersecurity ETFs list is the iShares Cybersecurity and Tech ETF. Founded in June 2019, it tracks the NYSE FactSet Global Cyber Security Index (INDEXNYSEGIS:NYFSSEC), and has a focus on developed and emerging markets in the cybersecurity industry.

The iShares Cybersecurity and Tech ETF has 37 holdings, including CyberArk Software (NASDAQ:CYBR) at a weight of 4.45 percent, Accton Technology (TPE:2345) at a 4.44 percent weight, Juniper Networks (NYSE:JNPR) at 4.39 percent and Okta (NASDAQ:OKTA) at 4.17 percent.

4. GlobalX Cybersecurity ETF (NASDAQ:BUG)

Company Profile

AUM: US$786.78 million
Expense ratio: 0.51 percent

The newest ETF on this list is the GlobalX Cybersecurity ETF, which was founded in October 2019. The ETF tracks a market-cap-weighted global index of companies selected based on revenue related to cybersecurity activities, as companies must generate at least 50 percent of their revenue from cybersecurity to be included.

The ETF has 22 holdings, with the top by weight being Fortinet (NASDAQ:FTNT) at a weight of 6.92 percent, CrowdStrike at 6.87 percent, Check Point Software Technologies (NASDAQ:CHKP) at 5.95 percent and Zscaler (NASDAQ:ZS) at 5.77 percent.

Securities Disclosure: I, Lauren Kelly, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The Malian government has begun seizing gold stockpiles at Barrick Gold’s (TSX:ABX,NYSE:GOLD) Loulo-Gounkoto mining site amidst a dispute over changes to the nation’s mining rules, enforcing a provisional order issued last week.

The seizure was confirmed by Barrick in a memo to staff, as the military-led government continues to claim a greater share of mining revenues from foreign operators, a Reuters report read.

The enforcement began on January 11, according to Barrick’s memo, which noted that the company may be compelled to suspend operations if the issue remains unresolved.

The Loulo-Gounkoto site contributes significantly to Barrick’s global production, accounting for about 14 percent of its estimated gold output for 2025. Barrick has an 80 percent interest in the operations, with the Malian government owning the remaining 20 percent.

While Barrick has not disclosed the exact volume of gold affected, internal estimates suggest that around 4 metric tons of gold, valued at approximately US$380 million based on current spot prices, are at stake. Multiple sources told Reuters Monday (January 13) that around 3 metric tons had already been seized from the site by helicopter on January 11, one of whom valued the seized gold at US$245 billion.

This comes amid ongoing tensions over the Malian government’s claims of unpaid taxes and dividends, which Barrick has disputed.

In a prior statement issued January 6, the company warned that it would be forced to halt operations if the government continued to restrict gold shipments. Barrick is seeking arbitration through the International Center for the Settlement of Investment Disputes.

Mali claims the company owes US$512 million in unpaid taxes and dividends, a claim Barrick has rejected.

The conflict has led to multiple detentions of Barrick executives, with the most recent occurring in November, after negotiations between the parties broke down. In early December, Reuters reported that the country had issued an arrest warrant for Barrick CEO Mark Bristow.

Mali’s mining code changes and financial overhaul

Gold is Mali’s primary export, contributing over 80 percent of the country’s total export revenues in 2023. The West African country’s government has been led by the military since a 2021 coup.

In 2023, Mali introduced a new mining code that aims to raise the country’s stake in mining operations from 20 to 35 percent.

The new code also allows the government to collect 7.5 percent of sales revenue when gold prices exceed US$1,500 per ounce.

Last year, following an audit into the mining sector, Mali began pursuing alleged back taxes and dividends owed by international mining companies.

Finance Minister Alousseni Sanou announced that the country expects to collect 750 billion CFA francs, about US$1.2 billion, from miners in the first quarter of 2025, following a similar collection of 500 billion CFA francs in late 2024.

Some companies have already come to agreements with the Malian government. For example, B2Gold (TSX:BTO,NYSEAMERICAN:BTG) reached a new agreement with the government last September for its Fekola operations that included financial settlements and Mali committing to expedite permitting for B2Gold’s Fekola underground mine.

Australia’s Resolute Mining (ASX:RSG,LSE:RSG) resolved a tax dispute with the government in November 2024 by agreeing to pay US$160 million after its CEO and two other executives were detained in Mali.

Barrick’s dispute, however, remains unresolved at this time.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Ernest Mast, President and Managing Director, Cygnus Metals Ltd. (TSXV: CYG) (‘Cygnus Metals’ or the ‘Company’), and his team, joined Robert Peterman, Chief Commercial Officer, Toronto Stock Exchange (TSX), to open the market to celebrate the Company’s new listing on TSX Venture Exchange.

Cygnus Metals Limited (TSXV: CYG) (ASX: CY5) is a diversified critical minerals exploration and development company with projects in Quebec, Canada and Western Australia. The Company is dedicated to advancing its Chibougamau Copper-Gold Project in Quebec with an aggressive exploration program to drive resource growth and develop a hub-and-spoke operation model with its centralised processing facility. In addition, Cygnus has quality lithium assets with significant exploration upside in the world-class James Bay district in Quebec, and REE and base metal projects in Western Australia. The Cygnus team has a proven track record of turning exploration success into production enterprises and creating shareholder value.

MEDIA CONTACT:
Laurie Gaborit
Advisor, Investor Relations
lgaborit@cygnusmetals.com
416.219.2049

Paul Armstrong
Read Corporate
+61 8 9388 1474

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236970

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com